THE SCIENCE BEHIND ENTROPY'S 75% IBS RESPONSE RATE

Irritable bowel syndrome (IBS) is framed as a disorder of central sensitization where the central nervous system hyper-interprets signals from the enteric nervous system as threatening pain. Phase 2a clinical trials evaluating TRP-8802 (oral psilocybin) achieved a 75% response rate in treatment-resistant IBS patients, demonstrating significant and durable reductions in symptom severity over a six to twelve-month follow-up period. Mechanistic evaluations indicate that psilocybin treatment substantially reduces gut-specific anxiety, measured via the Visceral Sensitivity Index, recalibrating interoceptive threat processing along the gut-brain axis. Rather than targeting localized gut inflammation or general systemic anxiety, psilocybin opens a critical window of neuroplasticity that alters how central neural networks process gastrointestinal sensory signals. Intravenous psilocin formulations (TRP-8803) offer key clinical advantages over oral psilocybin, including rapid onset, predictable pharmacokinetics, dose titratability, and shortened session durations that enhance scalability and safety.